Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jean-Phillipe Pettiloud"'
Autor:
Franck Madoux, Daniela Dreymuller, Jean-Phillipe Pettiloud, Radleigh Santos, Christoph Becker-Pauly, Andreas Ludwig, Gregg B. Fields, Thomas Bannister, Timothy P. Spicer, Mare Cudic, Louis D. Scampavia, Dmitriy Minond
Publikováno v:
Scientific Reports, Vol 6, Iss 1, Pp 1-17 (2016)
Abstract ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab. The majority of ADAM10 and ADAM17 inhibitor development has been focused on the discovery of compounds
Externí odkaz:
https://doaj.org/article/c6750ea01d4646cda1fe10c04ac5d8b2
Autor:
Radleigh G. Santos, Gregg B. Fields, Louis Scampavia, Jean-Phillipe Pettiloud, Andreas Ludwig, Daniela Dreymüller, Dmitriy Minond, Mare Cudic, Christoph Becker-Pauly, Franck Madoux, Thomas D. Bannister, Timothy P. Spicer
Publikováno v:
Scientific Reports
Scientific Reports, Vol 6, Iss 1, Pp 1-17 (2016)
Scientific reports 6, 11 (2016). doi:10.1038/s41598-016-0013-4
Scientific Reports, Vol 6, Iss 1, Pp 1-17 (2016)
Scientific reports 6, 11 (2016). doi:10.1038/s41598-016-0013-4
ADAM10 and ADAM17 have been shown to contribute to the acquired drug resistance of HER2-positive breast cancer in response to trastuzumab. The majority of ADAM10 and ADAM17 inhibitor development has been focused on the discovery of compounds that bin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08768f96f7c630133c853275602e2571
https://doi.org/10.1038/s41598-016-0013-4
https://doi.org/10.1038/s41598-016-0013-4